MEK inhibition induces caspases activation, differentiation blockade and PML/RARα degradation in acute promyelocytic leukaemia

British Journal of Haematology

Volumn 142, Issue 1, 2008, Pages 27-35

  Barbarroja, Nuria ^a   Siendones, Emilio ^b   Torres, Luis Arístides ^a   Luque, Ma Jose ^a   Martinez, Julio Manuel ^a   Dorado, Gabriel ^c   Velasco, Francisco ^a   Torres, Antonio ^a   López Pedrera, Chary ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Universidad Pablo de Olavide   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Acute promyelocytic leukaemia; All trans retinoic acid; MEK ERK; Promyelocytic leukaemia retinoic acid receptor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BETA ACTIN; CASPASE; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS;

EID: 44649115385     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07154.x     Document Type: Article

References (39)

1. Allan, L.A., Morrice, N., Brady, S., Magee, G., Pathak, S. Clarke, P.R. (2003) Inhibition of caspase-9 though phosphorylation al Thr 125 by ERK MAPK. Nature Cell Biology, 5, 647 654.
2. Andreeff, M., Jiang, S., Zhang, X., Konopleva, M., Estrov, Z., Snell, V.E., Xie, Z., Okcu, M.F., Sanchez-Williams, G., Dong, J., Estey, E.H., Champlin, R.C., Kornblau, S.M., Reed, J.C. Zhao, S. (1999) Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia, 13, 1881 1892.
3. Bonati, A., Rizzoli, V. Lunghi, P. (2006) Arsenic trioxide in hematological malignances: the new discovery of an ancient drug. Current Pharmaceutical Biotechnology, 7, 397 405.
4. Bruel, A., Benoit, G., De Nay, D., Brown, S. Lanotte, M. (1995) Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression. Leukemia, 9, 1173 1184.
5. Chan, I.T., Kutok, J.L., Williams, I.R., Cohen, S., Moore, S., Shigematsu, H., Shigematsu, H., Ley, T.J., Akashi, K., Le Beau, M.M. Gilliland, D.G. (2006) Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease. Blood, 108, 1708 1715.
6. Dash, A. Gilliland, D.G. (2001) Molecular genetics of acute myeloid leukaemia. Best Practice & Research Clinical Haematology, 14, 49 64.
7. Gianni, M. de Thé, H. (1999) In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia, 13, 739 749.
8. Gianni, M., Ponzanelli, I., Mologni, L., Reichert, U., Rambaldi, A., Terao, M. Garattini, E. (2000) Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death and Differentiation, 7, 447 460.
9. Jing, Y. (2004) The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukemia. Leukemia & Lymphoma, 45, 639 648.
10. Kambhampati, S., Verma, A., Li, Y., Parmar, S., Sassano, A. Platanias, L.C. (2004) Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leukemia & Lymphoma, 45, 2175 2185.
11. Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F. Berger, R. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated form a human acute promyelocytic leukemia (M3). Blood, 77, 1080 1086.
12. Lee, J.T. McCubrey, J.A. (2002) The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia, 16, 486 507.
13. Licht, J.D. Zelent, A. (2005) Retinoid and growth factor receptor signaling in APL. Blood, 105, 1381 1382.
14. López-Pedrera, C., Dobado-Berrios, P.M., Ros, R., Torres, A., García-Navarro, S., Jardí, M., Félez, J. Velasco, F. (2001) Signal transduction pathways underlying the expression of tissue factor and thrombomodulin in promyelocytic cells induced to differentiate by retinoid acid and dibutyryl cAMP. Thrombosis & Haemostasis, 85, 1031 1036.
15. López-Pedrera, Ch., Barbarroja, N., Buendia, P., Torres, A., Dorado, G. Velasco, F. (2004) Promyelocytic leukemia retinoid signaling targets regulate apoptosis, tissue factor and thrombomodulin expression. Haematologica, 89, 286 295.
16. Lunghi, P., Tabilio, A., Dall'Aglio, P.P., Ridolo, E., Carlo-Stella, C., Pelicci, P.G. Bonati, A. (2003) Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia, 17, 1783 1793.
17. McCubrey, J.A., May, W.S., Duronio, V. Mufson, A. (2000) Serine/threonine phosphorylation in cytokine signal transduction. Leukemia, 14, 9 21.
18. Milella, M., Kornblau, S.M., Estrov, Z., Carter, B.Z., Lapillonne, H., Harris, D., Konopleva, M., Zhao, S., Estey, E. Andreeff, M. (2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. Journal of Clinical Investigation, 108, 851 859.
19. Milella, M., Kornblau, S.M. Andreeff, M. (2003) The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Reviews in Clinical Experimental Hematology, 7, 160 190.
20. Milella, M., Precupanu, C.M., Gregorj, C., Ricciardi, M.R., Petrucci, M.T., Kornblau, S., Tafuri, A. Andreeff, M. (2005) Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Current Pharmaceutical Design, 11, 2779 2795.
21. Milella, M., Konopleva, M., Precupanu, C.M., Tabe, Y., Ricciardi, M.R., Gregorj, C., Collins, S.J., Carter, B.Z., D'Angelo, C., Petrucci, M.T., Foà, R., Cognetti, F., Tafuri, A. Andreeff, M. (2007) MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood, 109, 2121 2129.
22. Miranda, M.B., McGuire, T.F. Johnson, D.E. (2002) Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia, 16, 683 692.
23. Nagy, L., Thomazy, V.A., Shipley, G.L., Fesus, L., Lamph, W., Heyman, R.A., Chandraratna, R.A. Davies, P.J. (1995) Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Molecular Cell Biology, 15, 3540 3551.
24. Nason-Buchernal, K., Takle, G., Pace, U., Flynn, S., Allopenna, J., Martin, P., George, S.T., Goldberg, A.R. Dmitrovsky, E. (1998) Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene, 17, 1759 1768.
25. Nawata, R., Yujiri, T., Nakamura, Y., Ariyoshi, K., Takahashi, T., Sato, Y., Oka, Y. Tanizawa, Y. (2003) MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene, 22, 7774 7780.
26. Nervi, C., Ferrara, F.F., Fanelli, M., Rippo, M.R., Tomassini, B., Ferrucci, P.F., Ruthardt, M., Gelmetti, V., Gambacorti-Passerini, C., Diverio, D., Grignani, F., Pelicci, P.G. Testi, R. (1998) Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood, 92, 2244 2251.
27. Platanias, L.C. (2003) Map kinase signaling pathways and hematologic malignancies. Blood, 101, 4667 4679.
28. Puccetti, E. Rhudardt, M. (2004) Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. Leukemia, 18, 1169 1175.
29. Rego, E.M., Ruggero, D., Tribioli, C., Cattoretti, G., Kogan, S., Redner, R.L. Pandolfi, P.P. (2006) Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene, 25, 1974 1979.
30. Ricciardi, M.R., McQueen, T., Chism, D., Milella, M., Estey, E., Kaldjian, E., Sebolt-Leopold, J., Konopleva, M. Andreeff, M. (2005) Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia, 19, 1543 1549.
31. Sell, S. (2005) Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Reviews, 1, 197 205.
32. Siendones, E., Barbarroja, N., Torres, L.A., Buendia, P., Velasco, F., Dorado, G., Torres, A. López-Pedrera, C. (2007) Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematological Oncology, 25, 30 37.
33. Steelman, L.S., Pohner, S.C., Shelton, J.G., Franklin, R.A., Bertrand, F.E. McCubrey, J.A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18, 189 218.
34. Tallman, M.S. (2001) Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Blood, 15, 133 142.
35. Tallman, M.S., Nabhan, C., Feusner, J.H. Rowe, J.M. (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood, 99, 759 767.
36. Yen, A., Roberson, M.S., Varvayanis, S. Lee, A.T. (1998) Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MEP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Research, 58, 3163 3172.
37. Yoshida, H., Kitamura, K., Tannaka, K., Omura, S., Miyazaki, T., Hachiya, T., Ohno, R. Naoe, T. (1996) Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Research, 38, 2945 2948.
38. Zhu, J., Koken, M.H., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., Chen, Z. de Thé, H. (1997) Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA, 94, 3978 3983.
39. Zhu, J., Gianni, M., Kopf, E., Honore, N., Chelbi-Alix, M., Koken, M., Quignon, F., Rochette-Egly, C. de Thé, H. (1999) Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proceedings of the National Academy of Sciences of the USA, 96, 14807 14812.